These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36145390)

  • 21. Are We Forgetting About IgA? A Re-examination of Coronavirus Disease 2019 Convalescent Plasma.
    Verkerke H; Saeedi BJ; Boyer D; Allen JW; Owens J; Shin S; Horwath M; Patel K; Paul A; Wu SC; Wang J; Ho A; Maier CL; Zerra PE; Chonat S; Arthur CM; Roback JD; Neish AS; Lough C; Josephson CD; Stowell SR
    Transfusion; 2021 Jun; 61(6):1740-1748. PubMed ID: 34041759
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influential factor and trend of specific IgG antibody titer in coronavirus disease 2019 convalescents.
    Wu C; Liu W; Li G; Zhang Z; Xiao K; LE A
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2020 Oct; 45(10):1172-1175. PubMed ID: 33268577
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Seroprevalence of SARS-CoV-2 among potential convalescent plasma donors and analysis of their deferral pattern: Experience from tertiary care hospital in western India.
    Jain R; Mallya MV; Amoncar S; Palyekar S; Adsul HP; Kumar R; Chawla S
    Transfus Clin Biol; 2022 Feb; 29(1):60-64. PubMed ID: 34302953
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-SARS-CoV-2 Serology persistence over time in COVID-19 Convalescent Plasma Donors.
    De Giorgi V; West KA; Henning AN; Chen L; Holbrook MR; Gross R; Liang J; Postnikova E; Trenbeath J; Pogue S; Scinto T; Alter HJ; Cantilena CC
    medRxiv; 2021 Mar; ():. PubMed ID: 33758897
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
    Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
    Trials; 2021 May; 22(1):342. PubMed ID: 34001174
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Convalescent plasma as an adjunctive therapy for COVID-19: A single centre experience in Malaysia.
    Lee KT; Yeoh WC; Zainul NH; Syed Alwi SB; Low LL
    Med J Malaysia; 2021 Sep; 76(5):653-657. PubMed ID: 34508370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Convalescent plasma therapy in patients with severe COVID-19, A single-arm, retrospective study.
    Ghadami L; Hasibi M; Asadollahi-Amin A; Asanjarani B; Farahmand M; Abdollahi H
    Microb Pathog; 2022 Apr; 165():105482. PubMed ID: 35288278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Convalescent Plasma to Treat COVID-19: A Two-Center, Randomized, Double-Blind Clinical Trial.
    Ventura-Enríquez Y; Cabello-Gutiérrez C; Pérez-Calatayud ÁA; Cortina-De la Rosa E; Fareli-González CJ; Castillo-Juárez P; Carlos AP; Zavaleta-Martínez EO; Diaz-Padilla E; Murrieta S; Álvarez-Jiménez VD; Ponce-Medrano JAD; Casillas-Suárez C; Ocampo-Ocampo MA; Vargas-De-León C; Fernández-Sánchez V
    Life (Basel); 2022 Nov; 12(11):. PubMed ID: 36362922
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SARS-CoV-2 IgG Levels Allow Predicting the Optimal Time Span of Convalescent Plasma Donor Suitability.
    Laner-Plamberger S; Lindlbauer N; Weidner L; Gänsdorfer S; Weseslindtner L; Held N; Lauth W; Zimmermann G; Kern JM; Föttinger F; Ombres L; Jungbauer C; Rohde E; Grabmer C
    Diagnostics (Basel); 2022 Oct; 12(11):. PubMed ID: 36359411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial.
    Balcells ME; Rojas L; Le Corre N; Martínez-Valdebenito C; Ceballos ME; Ferrés M; Chang M; Vizcaya C; Mondaca S; Huete Á; Castro R; Sarmiento M; Villarroel L; Pizarro A; Ross P; Santander J; Lara B; Ferrada M; Vargas-Salas S; Beltrán-Pavez C; Soto-Rifo R; Valiente-Echeverría F; Caglevic C; Mahave M; Selman C; Gazitúa R; Briones JL; Villarroel-Espindola F; Balmaceda C; Espinoza MA; Pereira J; Nervi B
    PLoS Med; 2021 Mar; 18(3):e1003415. PubMed ID: 33657114
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of severe COVID-19 patients with either low- or high-volume of convalescent plasma
    Song ATW; Rocha V; Mendrone-Júnior A; Calado RT; De Santis GC; Benites BD; Costa-Lima C; Vargas T; Marques LS; Fernandes JC; Breda FC; Wendel S; Fachini R; Rizzo LV; Kutner JM; Avelino-Silva VI; Machado RRG; Durigon EL; Chevret S; Kallas EG
    Lancet Reg Health Am; 2022 Jun; 10():100216. PubMed ID: 35308034
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Functional convalescent plasma antibodies and pre-infusion titers shape the early severe COVID-19 immune response.
    Herman JD; Wang C; Loos C; Yoon H; Rivera J; Eugenia Dieterle M; Haslwanter D; Jangra RK; Bortz RH; Bar KJ; Julg B; Chandran K; Lauffenburger D; Pirofski LA; Alter G
    Nat Commun; 2021 Nov; 12(1):6853. PubMed ID: 34824251
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hospital-Based Donor Recruitment and Predonation Serologic Testing for COVID-19 Convalescent Plasma.
    Balcerek J; Trejo E; Levine K; Couey P; Kornberg ZV; Rogine C; Young C; Li PJ; Shy BR; Taylor JE; Bakhtary S; Friedlander T; Lynch KL; Bern C; Esensten JH
    Am J Clin Pathol; 2021 Mar; 155(4):515-521. PubMed ID: 33399201
    [TBL] [Abstract][Full Text] [Related]  

  • 34. COVID-19 Repeated Convalescent Plasma Collection: Analysis of 149 Donations from 88 French Military Health Workers.
    Conan PL; Ficko C; Chueca M; Rolland C; Javaudin O; Bigaillon C; Durand GA; Leparc-Goffart I; Verret C; Aletti M; Dutasta F; Savini H; Bosson JL; Martinaud C
    Transfus Med Hemother; 2021 Aug; 395(5):1-6. PubMed ID: 34580580
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
    Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Kinetics of SARS-CoV-2 antibody responses pre-COVID-19 and post-COVID-19 convalescent plasma transfusion in patients with severe respiratory failure: an observational case-control study.
    Klein MN; Wang EW; Zimand P; Beauchamp H; Donis C; Ward MD; Martinez-Hernandez A; Tabatabai A; Baddley JW; Bloch EM; Mullins KE; Fontaine MJ
    J Clin Pathol; 2022 Aug; 75(8):564-571. PubMed ID: 33893156
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Donors for SARS-CoV-2 Convalescent Plasma for a Controlled Clinical Trial: Donor Characteristics, Content and Time Course of SARS-CoV-2 Neutralizing Antibodies.
    Körper S; Jahrsdörfer B; Corman VM; Pilch J; Wuchter P; Blasczyk R; Müller R; Tonn T; Bakchoul T; Schäfer R; Juhl D; Schwarz T; Gödecke N; Burkhardt T; Schmidt M; Appl T; Eichler H; Klüter H; Drosten C; Seifried E; Schrezenmeier H
    Transfus Med Hemother; 2021 May; 48(3):137-147. PubMed ID: 34177417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Convalescent Plasma the Experience and Journey from Blockbuster to Incognito: A Single Centre Experience.
    Negi G; Kaur D; Jain A; Mohan YK; Meinia SK; Kaur P; Panda PK; Kalita D; Ravikant
    Recent Adv Antiinfect Drug Discov; 2023; 18(3):188-196. PubMed ID: 35733306
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utilization of the Abbott SARS-CoV-2 IgG II Quant Assay To Identify High-Titer Anti-SARS-CoV-2 Neutralizing Plasma against Wild-Type and Variant SARS-CoV-2 Viruses.
    Lin YJ; Evans DH; Robbins NF; Orjuela G; Hu Q; Samson R; Abe KT; Rathod B; Colwill K; Gingras AC; Tuite A; Yi QL; O'Brien SF; Drews SJ
    Microbiol Spectr; 2022 Oct; 10(5):e0281122. PubMed ID: 36125288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors associated with high antibody titer following coronavirus disease among 581 convalescent plasma donors: A single-center cross-sectional study in Japan.
    Suzuki T; Asai Y; Ide S; Fukuda S; Tanaka A; Shimanishi Y; Takahashi K; Terada M; Sato L; Sato M; Inada M; Yamada G; Miyazato Y; Akiyama Y; Nomoto H; Nakamoto T; Nakamura K; Togano T; Morioka S; Kinoshita-Iwamoto N; Saito S; Kutsuna S; Ohmagari N
    J Infect Chemother; 2022 Feb; 28(2):206-210. PubMed ID: 34756573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.